SecBot SecBot

VNDA drug pipeline

$3.81
−4.5% 1-day · Nov 16
Next catalyst
Dec 12, 2026
imsidolimab BLA filing · in 25 days
Typical move on FDA news
±10.1%
1-day, median of 18 events
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 neutral
Phase 3 trials
6
3 with results posted

Upcoming catalysts

3 dated
  1. Dec 12, 202625d
    imsidolimab
    BLA filing · Generalized Pustular Psoriasis
  2. Dec 12, 202625d
    imsidolimab
    PDUFA date · Generalized Pustular Psoriasis
  3. Dec 2026
    VQW-765
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since 2009 (schizophrenia) and 2024 (bipolar I disorder).

Fanapt iloperidone Updated Oct 28

What to watch

Fanapt has no hard binary catalyst in the next 12 months. Watch the Q3 2026 earnings call today (October 28) for the latest Fanapt prescription trends, as well as the December 12, 2026 PDUFA for imsidolimab (a different Vanda asset). The key long-term question is how quickly the next-gen asset BYSANTI (milsaperidone, approved February 2026) cannibalizes or replaces Fanapt revenue as generic iloperidone pressure builds.

Bull case
  • Fanapt prescription growth is accelerating: total prescriptions rose 31% YoY and new-to-brand prescriptions rose 32% YoY in Q2 2026, driven by the newer bipolar I disorder label expansion.
  • Fanapt generated $117.3M in net sales in 2025 (up 24% YoY) and represents 54% of Vanda's total revenue, making it the company's largest and fastest-growing commercial product.
  • Vanda developed BYSANTI (milsaperidone), an active metabolite of Fanapt approved as a new chemical entity in February 2026 with patent protection extending to the 2040s, providing a follow-on lifecycle strategy.
Bear case
  • Generic iloperidone is already available from at least 3 manufacturers, which limits pricing power and long-term revenue growth potential for Fanapt.
  • The FDA approval of BYSANTI (milsaperidone), Fanapt's own active metabolite, introduces a potential cannibalization risk if patients and prescribers switch to the newer chemical entity.
  • Vanda's total revenue is under pressure beyond Fanapt: HETLIOZ sales declined 66% YoY in Q2 2026 due to generic competition, and the company is burning cash according to some analysts.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed (FDA approval March 2021).

PONVORY ponesimod Updated Oct 28

What to watch

PONVORY itself has no upcoming binary catalyst; the next major Vanda event is the imsidolimab (Quimilza) PDUFA on December 12, 2026 for generalized pustular psoriasis, a separate drug. Watch Q3 2026 earnings (released today, Oct 28) for PONVORY's sales trajectory and any commentary on formulary access or market share trends in the competitive S1P modulator class.

Bull case
  • PONVORY is an FDA-approved, already-commercialized asset with a proven safety profile and over 10 years of clinical data, reducing regulatory risk.
  • Vanda acquired U.S. and Canadian rights for $100M in December 2023 and completed the FDA marketing authorization transfer, giving it full control over U.S. commercialization.
  • Q3 2026 PONVORY sales of $7.7M were up 10% year-over-year, and first-half 2026 sales of $14.1M were up 11% YoY, suggesting modest growth momentum.
Bear case
  • PONVORY operates in a crowded S1P modulator class facing generic fingolimod (Gilenya) pricing pressure, plus branded competition from Mayzent (siponimod, Novartis) and Zeposia (ozanimod, BMS).
  • PONVORY sales are modest and roughly flat: $27.4M in FY2025 (down 2% YoY) and $7.7M in Q3 2026 (down 2% sequentially from Q2 2026).
  • NCE-1 exclusivity expired in March 2025, opening the door for patent challenges; earliest generic entry could be as soon as November 2029 per DrugPatentWatch.
▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market since 2014. A potential DSWPD label expansion is at least 12-18 months away (sNDA submission and FDA review cycle ahead; no PDUFA date set).

HETLIOZ tasimelteon Updated Oct 28

What to watch

Watch for Vanda's DSWPD sNDA submission timeline and any FDA feedback from planned discussions; also monitor the formal evidentiary hearing on the jet lag rejection. Neither has a fixed date, so HETLIOZ-specific binary catalysts are not imminent. Vanda's near-term value is more tied to the imsidolimab PDUFA (December 12 2026) and Fanapt commercial trends than to HETLIOZ.

Bull case
  • Positive Phase 3 DSWPD data (Sept 2026): 37.1-minute sleep-onset shift vs placebo, p=0.022, with 60% of treated patients advancing sleep by >=30 minutes vs 15% on placebo, supporting a potential new label expansion
  • Q3 2026 HETLIOZ revenue bounced to $21.7M (including $7M shipment timing) from $5.6M in Q2, partly reflecting order lumpiness that could persist
  • Analyst consensus remains bullish on VNDA overall: 9 Buy/Strong Buy vs 2 Hold, with mean price target $11.50 (198% upside from the $3.86 reference price)
Bear case
  • Generic tasimelteon from Teva, Apotex, and MSN is already on the market, causing HETLIOZ sales to collapse 66% year-over-year in Q2 2026 to $5.6M; revenue erosion is structural, not temporary
  • Two FDA rejections for the jet lag indication (most recently Jan 2026) with a -14% 1-day stock decline; the formal hearing granted in June 2026 has an uncertain outcome
  • HETLIOZ is becoming a small part of Vanda's business (roughly 11% of Q2 revenue vs Fanapt at 71%), limiting any HETLIOZ-specific catalyst impact on the overall stock

Other drugs in filings and trials

no drug report yet
  • imsidolimab Next: BLA filing · Dec 12, 2026 Last: NDA filed · Oct 1, 2025
  • Quimilza Last: Orphan drug designation · Jul 1, 2026
  • Bysanti Last: PDUFA decision · Feb 21, 2026
  • NEREUS Last: Approval · Feb 11, 2026
  • tradipitant Last: NDA filed · Jan 7, 2026 1 trial
  • Trichostatin A 1 trial
  • VQW-765 1 trial

Past FDA events & how the stock moved

18 events
DateDrugEvent1 day5 days
Jul 1, 2026QuimilzaOrphan drug designation+1.5%+4.3%
May 1, 2026QuimilzaOrphan drug designation+6.5%−11.6%
Feb 21, 2026BysantiPDUFA decision+41.5%+54.7%
Feb 20, 2026BYSANTIApproval+33.6%+46.1%
Feb 11, 2026NEREUSApproval−17.5%−17.8%
Jan 8, 2026HETLIOZComplete response letter−14.2%−12.8%
Jan 7, 2026HETLIOZPDUFA decision−9.7%−5.3%
Jan 7, 2026tradipitantNDA filed−9.7%−5.3%
Dec 30, 2025tradipitantPDUFA decision+22.5%+18.6%
Dec 30, 2025NEREUSApproval+22.5%+18.6%
Dec 5, 2025tradipitantPartial clinical hold+18.1%+19.8%
Nov 26, 2025tradipitantPartial clinical hold+7.2%+4.0%
Oct 1, 2025imsidolimabNDA filed+3.4%+9.4%
Oct 1, 2025imsidolimabBLA filed+3.4%+9.4%
Oct 1, 2025tradipitantPartial clinical hold+3.4%+9.4%
Mar 18, 2021PONVORYApproval−0.3%−10.4%
Dec 1, 2020HETLIOZApproval+10.5%+11.8%
Jan 31, 2014HETLIOZApproval−14.9%−13.0%

Clinical trials

7 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
VQW-765Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderPhase 3Active not recruiting500Dec 2026
HETLIOZEvaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)Phase 3Completed43Sep 4, 2026
Trichostatin ASafety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisPhase 2Active not recruiting50Sep 2026
TradipitantOpen Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisPhase 3Completed17Mar 30, 2026
TradipitantEvaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisPhase 3Completed · results979Feb 21, 2025
Double-blind 200 mg imsidolimabStudy to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPPhase 3Terminated · results42Jul 12, 2024
FanaptEfficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaPhase 3Completed · results593Sep 26, 2006